Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ABCL

AbCellera Biologics Inc

11.57

Aug 20 • 3:59 PM ET -0.44 (-3.66%)

11.54

Aftermarket • 7:55 PM ET -0.03 (-0.26%)

Healthcare Biotechnology Canada Mid NASD

Peers: RCUS CGON TNGX KYMR RYTM BMRN CRNX INCY KRYS AXSM

| Held by: IBB CPAI SPDW IDNA GWX ONEQ AVUS BBC AVSC PDN

Index	-
Market Cap	3.75B
Enterprise Value	3.32B
Income	-164.66M
Sales	66.17M
Book/sh	2.92
Cash/sh	1.74
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	562
IPO	Dec 11, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	56.66
P/B	3.96
P/C	6.63
P/FCF	-
EV/EBITDA	-
EV/Sales	50.17
Quick Ratio	12.63
Current Ratio	12.77
Debt/Eq	0.15
LT Debt/Eq	0.15
Option/Short	Yes / Yes

EPS (ttm)	-0.54
EPS next Y	-0.71
EPS next Q	-0.17
EPS this Y	-33.88%
EPS next Y	-8.99%
EPS next 5Y	-20.31%
EPS past 3/5Y	- -
Sales past 3/5Y	-46.31% -20.27%
EPS Y/Y TTM	2.49%
Sales Y/Y TTM	101.28%
EPS Q/Q	-55.98%
Sales Q/Q	-76.29%
Earnings	Aug 05 AMC
EPS/Sales Surpr.	-9.76% -48.39%

Insider Own	23.05%
Insider Trans	0.00%
Inst Own	36.62%
Inst Trans	3.43%
ROA	-12.15%
ROE	-17.30%
ROIC	-16.05%
Gross Margin	50.74%
Oper. Margin	-340.25%
Profit Margin	-248.83%
SMA20	43.15%
SMA50	63.31%
SMA200	144.61%
Trades

Shs Outstand	306.47M
Shs Float	249.35M
Short Float	19.38%
Short Ratio	5.91
Short Interest	48.32M
52W High	12.15 -4.77%
52W Low	2.74 321.49%
Volatility	7.83% 9.01%
ATR (14)	0.82
RSI (14)	77.12
Beta	1.36
Rel Volume	0.76
Avg Volume	8.18M
Volume	6,181,576

Perf Week	5.47%
Perf Month	101.92%
Perf Quarter	153.17%
Perf Half Y	259.32%
Perf YTD	238.30%
Perf Year	177.46%
Perf 3Y	110.75%
Perf 5Y	-27.87%
Perf 10Y	-
Recom	1.00
Target Price	17.12
Prev Close	12.01
Price	11.57
Change %	-3.66%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-07-26	Upgrade	The Benchmark Company	Hold → Buy	$11
May-05-26	Initiated	Cantor Fitzgerald	Overweight	$7
Nov-07-25	Downgrade	Leerink Partners	Outperform → Market Perform	$4
Jul-07-25	Resumed	Leerink Partners	Outperform	$5
Aug-20-24	Downgrade	The Benchmark Company	Buy → Hold
Feb-22-24	Upgrade	The Benchmark Company	Hold → Buy	$9
Dec-05-23	Initiated	KeyBanc Capital Markets	Overweight	$6
Nov-06-23	Downgrade	The Benchmark Company	Buy → Hold
Oct-13-23	Resumed	Piper Sandler	Overweight	$20
Feb-28-23	Initiated	Cowen	Outperform
Dec-15-22	Initiated	Goldman	Buy	$30
Nov-16-22	Initiated	Truist	Buy	$29
Dec-21-21	Initiated	The Benchmark Company	Buy	$27
Nov-19-21	Initiated	Piper Sandler	Overweight	$33
Jan-05-21	Initiated	SVB Leerink	Outperform	$45
Jan-05-21	Initiated	Stifel	Buy	$59
Jan-05-21	Initiated	Credit Suisse	Outperform	$52
Jan-05-21	Initiated	BMO Capital Markets	Outperform	$48
Jan-05-21	Initiated	Berenberg	Buy	$53

Show Previous Ratings

Aug-13-26 12:05AM	AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants (Business Wire) +5.94%
Aug-11-26 04:01PM	AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (Business Wire) +6.10%
Aug-10-26 10:31PM	Why Did ABCL, REPL, ABNB Stocks Hit 52-Week Highs Today? (Stocktwits) +34.78%
12:15PM	Hot-Flash Drug Trial Result Sends AbCellera Up as Much as 41% (Bloomberg)
12:05PM	AbCellera Stock Jumps 33% on a Positive Menopause Trial (GuruFocus.com)
08:45AM	Loading…
08:45AM	AbCellera shares surge 22% after ABCL635 delivers positive Phase 2 results (InvestorsHub)
07:23AM	This Biotech's Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News. (Barrons.com)
07:00AM	AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile (Business Wire)
06:52AM	ABCL Stock On Track For Best Day In Nearly 4.5 Years After Positive Phase 2 Menopause Drug Data (Stocktwits)
06:52AM	ABCL Stock Has Rallied 100% This Year Now All Eyes Are On AbCelleras Menopause Drug Data (Stocktwits)
Aug-07-26 04:30PM	AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026 (Business Wire) +6.13%
Aug-06-26 01:01AM	AbCellera Biologics Inc (ABCL) (Q2 2026) Earnings Call Highlights: Strong Pipeline Progress and ... (GuruFocus.com) +10.30%
Aug-05-26 04:05PM	AbCellera Reports Q2 2026 Business Results (Business Wire)
Jul-29-26 07:00AM	AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions (Business Wire)
Jul-23-26 09:05AM	An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers (PR Newswire)
08:45AM	Loading…
Jul-15-26 08:45AM	As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22 (PR Newswire)
Jul-07-26 04:05PM	AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026 (Business Wire) -7.67%
Jul-06-26 09:00AM	AbCellera Appoints Dr. Lynn Seely to its Board of Directors (Business Wire)
Jul-01-26 09:00AM	As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the Data (PR Newswire)
Jun-28-26 11:56PM	Why Did SLS, MRNA, ABCL Stocks Surge To 52-Week Highs Last Week? (Stocktwits)
Jun-17-26 08:50AM	Jazz Pharmaceuticals and AbCellera Partner on Antibody Programs for Solid Tumors (InvestorsHub) +6.88%
07:00AM	Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies (PR Newswire)
Jun-05-26 09:00AM	AbCellera Appoints Dr. Victor Sandor to its Board of Directors (Business Wire) -11.77%
May-12-26 03:07AM	AbCellera Biologics Inc (ABCL) Q1 2026 Earnings Call Highlights: Promising Advancements Amid ... (GuruFocus.com) -5.71%
May-11-26 04:05PM	AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635 (Business Wire)
May-07-26 04:05PM	AbCellera to Present at Upcoming Investor Conferences in May and June 2026 (Business Wire) +8.71%
Apr-20-26 09:00AM	AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call (Business Wire)
Apr-01-26 04:05PM	AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026 (Business Wire)
Mar-04-26 11:50AM	AbCellera Biologics Pivots to Pipeline as ABCL635 Phase II Hot Flash Data Nears, Exec Says (MarketBeat)
Feb-26-26 02:28PM	AbCellera Biologics (ABCL) Pivots to Clinical Stage as 2025 Revenue Hits $75M (Insider Monkey) +12.54%
08:02PM	Loading…
Feb-25-26 08:02PM	AbCellera Biologics Inc. Q4 2025 Earnings Call Summary (Moby)
03:51AM	What Sparked AbCellera Biologics To Soar Over 9% After Hours (Benzinga)
12:00AM	AbCellera Biologics Inc (ABCL) Q4 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges (GuruFocus.com)
Feb-24-26 09:55PM	AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +6.27%
06:26PM	AbCellera Biologics Q4 Earnings Call Highlights (MarketBeat)
04:05PM	AbCellera Reports Full Year 2025 Business Results (Business Wire)
Feb-19-26 07:30AM	3 New Stocks SoftBank Is Betting Big on in 2026 (Barchart)
Feb-18-26 09:43AM	SoftBank Adds TwentyOne Capital, Exits Nvidia in Q4 Portfolio Shift (GuruFocus.com)
Feb-11-26 04:05PM	AbCellera to Present at Upcoming Investor Conferences in March and April 2026 (Business Wire) -6.07%
Feb-02-26 07:49PM	AbCellera Biologics Inc. (ABCL): A Bull Case Theory (Insider Monkey)
Jan-29-26 01:49PM	What Does Wall Street Think About AbCellera Biologics Inc. (ABCL)? (Insider Monkey)
Jan-22-26 04:05PM	AbCellera to Report Full Year 2025 Financial Results on February 24, 2026 (Business Wire) +8.41% -8.62%
Jan-14-26 08:07PM	AbCellera Biologics Pivots to Internal Pipeline at JPMorgan, Teases Key Milestones for 2026 (MarketBeat)
Jan-12-26 09:00AM	AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause (Business Wire)
Dec-08-25 04:05PM	AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 (Business Wire)
Dec-04-25 10:09PM	AbCellera Biologics Inc (ABCL) Down 23% Since Q3 2025 Results (Insider Monkey)
Nov-25-25 08:16AM	AbCellera Biologics Inc. (ABCL) is a Buy at Stifel Nicolaus despite Wider Q3 Net Loss (Insider Monkey)
Nov-18-25 06:17AM	Why Wall Street Maintains Buy Stance on AbCellera Biologics Inc. (ABCL) Amid Business Model Evolution? (Insider Monkey)
Nov-07-25 12:12AM	AbCellera Biologics Inc (ABCL) Q3 2025 Earnings Call Highlights: Transition to Clinical-Stage ... (GuruFocus.com) -13.69%
Nov-06-25 05:45PM	AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	AbCellera Reports Q3 2025 Business Results (Business Wire)
Oct-21-25 10:47PM	AbCellera Biologics Inc. (ABCL): A Bull Case Theory (Insider Monkey)
Oct-07-25 04:05PM	AbCellera to Participate at Upcoming Investor Conferences in November and December 2025 (Business Wire) +6.93%
Sep-30-25 09:40AM	Is ABCELLERA BIOLG (ABCL) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-29-25 04:05PM	AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025 (Business Wire)
12:00PM	AbCellera Biologics Inc. (ABCL) is a Great Momentum Stock: Should You Buy? (Zacks)
Sep-21-25 09:26AM	New CMO Appointment Strengthens AbCellera Biologics Inc. (ABCL)'s Push Into Immunology and Beyond (Insider Monkey)
Sep-20-25 02:43AM	AbCellera Biologics Inc. (ABCL) Appoints Chief Medical Officer (Insider Monkey)
Sep-15-25 08:17AM	TD Cowen Reiterates Buy Rating on ABCL After AbCellera Biologics Dosed First Participants of ABCL575 (Insider Monkey)
Sep-10-25 09:07AM	AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer (Business Wire)
Aug-28-25 05:04AM	AbCellera Biologics Inc. (ABCL) Launches First Human Trial for Menopause Therapy (Insider Monkey)
Aug-27-25 09:00AM	AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575 (Business Wire)
Aug-25-25 11:56PM	Truist Financial Reiterates a Buy Rating on AbCellera Biologics (ABCL), Sets a $10 PT (Insider Monkey)
Aug-17-25 06:10PM	AbCellera Biologics (ABCL) Advances Proprietary Pipeline with Promising Phase 1 Trial Results (Insider Monkey)
Aug-12-25 04:05PM	AbCellera to Participate at Upcoming Investor Conferences in September (Business Wire) -5.11% +7.26%
Aug-08-25 03:42AM	AbCellera Biologics Inc (ABCL) Q2 2025 Earnings Call Highlights: Revenue Surge and Clinical ... (GuruFocus.com)
Aug-07-25 06:20PM	AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:05PM	AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms (Business Wire)
Aug-05-25 05:55PM	Myriad Genetics (MYGN) Q2 Earnings and Revenues Surpass Estimates (Zacks) -5.50%
Jul-31-25 10:00AM	AbCellera Biologics Inc. (ABCL) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jul-24-25 10:06AM	AbCellera Biologics Inc. (ABCL): A Bull Case Theory (Insider Monkey)
Jul-22-25 11:03AM	Leerink Partners Affirms Outperform Rating on AbCellera Biologics (ABCL) Following Pivot (Insider Monkey)
09:39AM	Strength Seen in ABCELLERA BIOLG (ABCL): Can Its 15.0% Jump Turn into More Strength? (Zacks)
Jul-07-25 04:05PM	AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025 (Business Wire) +6.05%
09:11AM	Truist Financial Lowers PT on AbCellera Biologics (ABCL) to $10 From $28, Keeps a Buy Rating (Insider Monkey)
Jun-25-25 04:09AM	AbCellera Biologics Secures Patent Validity Affirmation for Microfluidic Cell Culture Technology (Insider Monkey)
Jun-09-25 09:13AM	AbCellera Biologics Inc. (ABCL): A Bull Case Theory (Insider Monkey)
Jun-03-25 12:00PM	ABCELLERA BIOLG (ABCL) Upgraded to Buy: Here's Why (Zacks) +7.94%
Jun-02-25 06:45PM	Why AbCellera Biologics Stock Raced Nearly 6% Higher Today (Motley Fool) +5.94%
May-30-25 01:00PM	AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 (Business Wire)
May-21-25 11:21AM	AbCellera Biologics Inc. (ABCL): Analysts See 474% Upside Potential (Insider Monkey)
May-14-25 05:00PM	AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause (Business Wire)
May-12-25 03:30PM	AbCelleras Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit (Business Wire)
May-09-25 07:30PM	AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting (Business Wire)
11:22AM	Q1 2025 Abcellera Biologics Inc Earnings Call (Thomson Reuters StreetEvents)
03:50AM	AbCellera Biologics Inc (ABCL) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
May-08-25 06:05PM	AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	AbCellera Reports Q1 2025 Business Results (Business Wire)
May-07-25 12:39PM	AbCellera Biologics Q1 2025 Earnings Preview (Seeking Alpha)
10:45AM	AbCellera Biologics Inc (ABCL) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Apr-29-25 03:00PM	AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025 (Business Wire)
Apr-23-25 10:14AM	Is AbCellera Biologics Inc. (ABCL) the Best Canadian Penny Stock to Invest in Now? (Insider Monkey)
Apr-16-25 11:59PM	AbCellera: Attractively Priced But A Catalyst Is Needed (Seeking Alpha)
Apr-08-25 04:05PM	AbCellera to Participate at Upcoming Investor Conferences in May and June (Business Wire) -5.85% +12.44%
Apr-03-25 04:05PM	AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025 (Business Wire) -5.86%
Mar-25-25 04:30PM	AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025 (Business Wire)
Feb-28-25 02:18PM	Q4 2024 Abcellera Biologics Inc Earnings Call (Thomson Reuters StreetEvents) -11.47%
02:43AM	AbCellera Biologics Inc (ABCL) Q4 2024 Earnings Call Highlights: Strategic Shifts Amid ... (GuruFocus.com)
Feb-27-25 10:15PM	AbCellera Biologics (ABCL) Q4 2024 Earnings Call Transcript (Motley Fool)
06:15PM	AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Misses Revenue Estimates (Zacks)

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Veronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

CEODr. Carl L.G. Hansen Ph.D.

Chief Financial OfficerMr. Andrew Booth M.B.A.

CTO & DirectorDr. Veronique Lecault Ph.D.

J.D.Mr. Tryn T. Stimart Esq.

Vice President of OperationsMr. Andrew Knowles M.Sc.

Open in Screener

IONS

Ionis Pharmaceuticals Inc

58.76

Aug 20 • 3:59 PM ET -2.04 (-3.36%)

58.82

Aftermarket • 7:30 PM ET +0.06 (0.10%)

Healthcare Biotechnology USA Mid NASD

IONS Ionis Pharmaceuticals Inc daily Stock Chart

Peers: ALNY ARWR BMRN JAZZ ASND CRSP RARE INCY VRTX NBIX

| Held by: VTI VB VBK VXF XBI CGGR IBB IWP SCHA IWR

Index	-
Market Cap	9.76B
Enterprise Value	9.90B
Income	-564.78M
Sales	873.76M
Book/sh	2.65
Cash/sh	12.36
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	1402
IPO	May 17, 1991

P/E	-
Forward P/E	-
PEG	-
P/S	11.18
P/B	22.13
P/C	4.75
P/FCF	-
EV/EBITDA	-
EV/Sales	11.33
Quick Ratio	7.73
Current Ratio	7.89
Debt/Eq	4.98
LT Debt/Eq	4.95
Option/Short	Yes / Yes

EPS (ttm)	-3.47
EPS next Y	-1.93
EPS next Q	-1.22
EPS this Y	-53.62%
EPS next Y	47.16%
EPS next 5Y	-
EPS past 3/5Y	-7.82% 5.62%
Sales past 3/5Y	17.12% 5.29%
EPS Y/Y TTM	-98.12%
Sales Y/Y TTM	-7.49%
EPS Q/Q	-202.29%
Sales Q/Q	-40.73%
Earnings	Jul 29 BMO
EPS/Sales Surpr.	36.17% 41.73%

Insider Own	1.96%
Insider Trans	-23.36%
Inst Own	107.90%
Inst Trans	-0.23%
ROA	-18.89%
ROE	-105.42%
ROIC	-21.59%
Gross Margin	95.66%
Oper. Margin	-68.09%
Profit Margin	-64.64%
SMA20	4.79%
SMA50	-8.60%
SMA200	-20.66%
Trades

Shs Outstand	165.64M
Shs Float	162.93M
Short Float	13.18%
Short Ratio	7.44
Short Interest	21.47M
52W High	86.74 -32.26%
52W Low	41.71 40.89%
Volatility	3.53% 3.52%
ATR (14)	2.21
RSI (14)	49.96
Beta	0.42
Rel Volume	0.74
Avg Volume	2.88M
Volume	2,124,846

Perf Week	5.17%
Perf Month	8.79%
Perf Quarter	-21.72%
Perf Half Y	-29.33%
Perf YTD	-25.72%
Perf Year	37.26%
Perf 3Y	51.25%
Perf 5Y	49.67%
Perf 10Y	75.98%
Recom	1.56
Target Price	88.19
Prev Close	60.80
Price	58.76
Change %	-3.36%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-19-26	Initiated	BMO Capital Markets	Market Perform	$60
Jul-16-26	Downgrade	Wolfe Research	Outperform → Peer Perform
May-19-26	Initiated	Citigroup	Buy	$115
Apr-21-26	Initiated	Canaccord Genuity	Buy	$110
Apr-10-26	Resumed	Raymond James	Outperform	$104
Jan-28-26	Resumed	Barclays	Overweight	$95
Oct-08-25	Upgrade	JP Morgan	Neutral → Overweight	$80
Sep-26-25	Upgrade	Goldman	Sell → Neutral	$65
Sep-03-25	Upgrade	BMO Capital Markets	Market Perform → Outperform	$70
Jul-31-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$62
Jul-01-25	Upgrade	Barclays	Equal Weight → Overweight	$57
Apr-07-25	Initiated	H.C. Wainwright	Buy	$45
Mar-31-25	Initiated	Redburn Atlantic	Neutral	$39
Aug-02-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$67 → $60
Jul-24-24	Upgrade	Leerink Partners	Market Perform → Outperform	$53 → $62
Jul-16-24	Resumed	Jefferies	Buy	$29 → $75
Jun-14-24	Upgrade	Bernstein	Underperform → Mkt Perform	$44
Apr-10-24	Upgrade	Wolfe Research	Peer Perform → Outperform	$58
Jan-02-24	Upgrade	BofA Securities	Neutral → Buy	$52 → $62
Oct-23-23	Upgrade	BofA Securities	Underperform → Neutral	$33 → $52

Show Previous Ratings

Aug-20-26 07:00AM	Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026 (Business Wire)
Jul-31-26 03:29PM	Is The Recent Pullback In Alnylam Stock An Opportunity Or A Trap? (Trefis)
Jul-29-26 05:02PM	Ionis Pharmaceuticals Inc (IONS) Q2 2026 Earnings Call Highlights: Robust Revenue Growth and ... (GuruFocus.com)
07:24AM	Ionis Pharmaceuticals: Q2 Earnings Snapshot (Associated Press)
07:05AM	Ionis announces Dr. Frank Bennett, chief scientific officer, to retire (Business Wire)
07:00AM	Loading…
07:00AM	Ionis reports second quarter 2026 financial results and highlights progress on key programs (Business Wire)
06:02AM	Biogen Raises Earnings Guidance as Growth Portfolio Outpaces Legacy Blockbuster Drugs (Barrons.com)
Jul-23-26 11:30AM	Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% - HBSS (PR Newswire)
11:00AM	Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company? (Trefis)
Jul-22-26 06:44PM	ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data (Stocktwits)
Jul-15-26 07:05AM	Ionis to hold second quarter 2026 financial results webcast (Business Wire)
Jul-14-26 09:16AM	Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease (Business Wire)
Jul-13-26 08:15AM	Biogen Stock Is Upgraded to Buy Ahead of Key Alzheimer's Drug Study Details (Barrons.com)
07:00AM	Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome (Business Wire)
02:00AM	Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer's? (Barrons.com)
08:57AM	Loading…
Jul-10-26 08:57AM	Cathie Wood Dumps AMD, Doubles Down on Meta Stock (GuruFocus.com) -9.37%
08:14AM	Beyond The Breakout Drug: Is BridgeBio Pharma Stock A Buy On Its Next Act? (Trefis)
07:35AM	The Long Climb Back For Ionis Stock (Trefis)
Jul-09-26 03:06PM	BBIO Stock Surges 16% As AstraZeneca-Ionis Heart Drug Trial Misses Goal BofA Calls Failure A Big Surprise (Stocktwits) -23.90%
02:02PM	AstraZeneca Slides 9.9% After Heart Drug Trial Misses Late-Stage Goal (GuruFocus.com)
11:27AM	AstraZeneca Gets a Rare Clinical Black Eye (Moby)
10:38AM	AstraZeneca, Ionis Stocks Stumble After Heart Drug Fails Key Trial (The Wall Street Journal)
10:24AM	Stocks to Watch: PepsiCo, Salesforce, AstraZeneca (The Wall Street Journal)
09:04AM	AstraZeneca, Ionis Shares Slide After Wainua Misses Target in Heart Disease Trial (The Wall Street Journal)
08:40AM	AstraZeneca Falls After Wainua Heart Disease Trial Fails (GuruFocus.com)
07:38AM	AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars. (Barrons.com)
07:14AM	AstraZeneca stock drops 9% after Wainua heart drug trial fails (Quartz)
07:11AM	IONS Stock Heads Toward Biggest Single-Day Slump In Over 5 Years Retail Calls It Opportunity Of A Lifetime (Stocktwits)
06:00AM	Ionis Pharma dives on drug trial failure, and other early market movers (MarketWatch)
04:43AM	AstraZeneca Shares Plunge on Rare Trial Failure of Heart Drug (Bloomberg)
03:54AM	Loading…
03:54AM	AstraZeneca, Ionis drug fails big heart disease study in major setback (BioPharma Dive)
02:00AM	Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy (Business Wire)
Jul-06-26 07:00AM	Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome (Business Wire)
Jun-26-26 06:17AM	Ionis grants Recordati rights to zilganersen for Alexander disease (Hospital Management)
Jun-25-26 02:59AM	Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S. (Business Wire)
Jun-24-26 07:54PM	IONS Stock Jumps 4% After-Hours Goldman Sachs Lifts Price Target On Tryngolza Approval (Stocktwits)
02:37PM	TRYNGOLZA (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG) (Business Wire)
12:50PM	Ionis, with new FDA nod, hits a commercial inflection point (BioPharma Dive)
Jun-23-26 06:21AM	How Kardigan spun deal leftovers into a $400M IPO (BioPharma Dive)
Jun-19-26 08:24AM	QURE Was Just the Beginning: 5 Biotech Catalysts Im Watching Now (InvestorPlace)
Jun-08-26 07:00AM	Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors (Business Wire)
Jun-04-26 07:00AM	Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses (Business Wire)
May-29-26 06:16AM	GSKs hepatitis B drug touts functional curative potential in double Phase III win (Clinical Trials Arena)
May-28-26 04:27PM	JPMorgan says large-cap biotech is back as profits and pipelines fuel upside (Investing.com)
04:45AM	Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B (Business Wire)
May-27-26 12:00PM	A New, Powerful Cholesterol-Lowering Drug Is on the Horizon (The Wall Street Journal)
07:34AM	Tryngolza shows efficacy in severe hypertriglyceridemia as approval verdicts loom (Clinical Trials Arena)
May-19-26 09:34AM	StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls (The Fly)
May-14-26 07:05AM	Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer's disease (Business Wire)
May-06-26 07:08PM	Tweedy Browne's Strategic Moves: Ionis Pharmaceuticals Inc. Sees Significant Reduction (GuruFocus.com)
May-04-26 07:05AM	Ionis to host 2026 virtual Annual Meeting of Stockholders (Business Wire)
May-01-26 07:05AM	Ionis to present at upcoming investor conferences (Business Wire)
Apr-29-26 04:53PM	Ionis Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary (Moby)
07:18AM	Ionis Pharmaceuticals: Q1 Earnings Snapshot (Associated Press)
07:00AM	Ionis reports first quarter 2026 financial results and highlights progress on key programs (Business Wire)
Apr-28-26 02:06AM	Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B (Business Wire)
Apr-21-26 10:04AM	This Pharma Stock Is Up 460% Over the Past Year. What Could Be Key to Future Gains. (Barrons.com)
07:00AM	Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting (Business Wire)
Apr-15-26 07:05AM	Ionis to hold first quarter 2026 financial results webcast (Business Wire)
Apr-10-26 09:37AM	Nike downgraded, IBM initiated: Wall Street's top analyst calls (The Fly)
Mar-23-26 07:00AM	Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review (Business Wire)
Mar-09-26 07:00AM	Ionis announces changes to Board of Directors (Business Wire)
Feb-28-26 07:36AM	Ionis Pharmaceuticals CEO Teases Late-June Olezarsen Launch After FDA Priority Review Acceptance (MarketBeat)
Feb-27-26 07:00AM	Ionis to present new data supporting DAWNZERA (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting (Business Wire)
Feb-26-26 11:53PM	Needham Lifts PT on Ionis Pharmaceuticals (IONS) to $103 From $90 (Insider Monkey)
10:04PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
09:18AM	Ionis Q4 Earnings & Sales Beat, Stock Down on Soft 2026 Outlook (Zacks)
07:00AM	Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG) (Business Wire)
Feb-25-26 04:32PM	Ionis Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary (Moby) -5.29%
04:04PM	Ionis Pharmaceuticals Inc (IONS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
02:21PM	Ionis Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
12:48PM	Ionis Guides Below 2026 Sales Views Despite Strong Growth From Lead Drug (Benzinga)
12:30PM	Ionis Pharmaceuticals (IONS) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
12:15PM	Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:12AM	Ionis Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs (Business Wire)
Feb-20-26 09:15AM	Exploring Analyst Estimates for Ionis Pharmaceuticals (IONS) Q4 Earnings, Beyond Revenue and EPS (Zacks)
Feb-19-26 07:05AM	Ionis to present at upcoming investor conferences (Business Wire)
Feb-18-26 10:00AM	Analysts Estimate Catalyst Pharmaceutical (CPRX) to Report a Decline in Earnings: What to Look Out for (Zacks)
Feb-17-26 02:58PM	Ionis updates time for fourth quarter and full year 2025 financial results webcast (Business Wire)
12:09PM	RNA-targeting small molecules: a new frontier of drug discovery (Pharmaceutical Technology)
Feb-11-26 10:00AM	Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
07:05AM	Ionis to hold fourth quarter and full year 2025 financial results webcast (Business Wire)
Feb-04-26 08:31AM	GSK's Q4 Earnings & Sales Beat Estimates, Stock Up on '26 Outlook (Zacks)
Feb-03-26 04:40PM	The pioneering physician behind groundbreaking ASO therapy (CNBC TV)
12:00PM	Tweedy Browne's Strategic Moves: Significant Increase in CNH Industrial NV (GuruFocus.com)
Jan-22-26 11:55AM	Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema (Zacks)
Jan-21-26 04:58PM	Cathie Wood Has 13 Big Ideas For 2026: Here's The Ark Invest List And Stocks To Watch (Benzinga)
07:00AM	DAWNZERA (donidalorsen) approved in the European Union for hereditary angioedema (HAE) (Business Wire)
Jan-12-26 04:18PM	JPM Preannouncements: Why Alnylam And Sarepta Lost, But Day One Won (Investor's Business Daily)
12:02PM	National Bank of Canada Sees Significant Reduction in Tweedy Browne International Value's Portfolio (GuruFocus.com)
10:56AM	JPM Preannouncements Take Their Toll As Alnylam Slides, Tempus, Day One Pop (Investor's Business Daily)
07:00AM	Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts (Business Wire)
Jan-08-26 12:33PM	GSK's Chronic Hepatitis B Drug Meets Goals in Two Late-Stage Studies (Zacks)
10:31AM	Cathie Wood Dumps $12.7 Million Worth of Meta Stock Amid Ray-Ban Smart Glasses Delay, Ark Loads Up On This Gaming Platform (Benzinga)
Jan-07-26 06:23AM	GSK, Ionis claim study success for RNA-based hepatitis B drug (BioPharma Dive)
02:15AM	Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B (Business Wire)
Jan-06-26 07:05AM	Ionis to present at 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-05-26 08:25AM	Ardelyx (ARDX) Moves 5.5% Higher: Will This Strength Last? (Zacks)
Dec-22-25 10:11AM	What Awaits These 4 Biotech Stocks That More Than Doubled in 2025 (Zacks)

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

FounderDr. Brett P. Monia Ph.D.

M.B.A.Ms. Elizabeth L. Hougen M.A.

Executive VPMr. Patrick R. O'Neil Esq.

Executive Vice President & Head of ResearchDr. Eric E. Swayze Ph.D.

Executive Vice President of Corporate & Development OperationsMr. Brian Birchler

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hayden Michael R	Director	Jul 30 '26	Buy	53.38	15,000	800,700	19,000	Jul 31 04:42 PM
Hayden Michael R	Director	Jul 31 '26	Buy	51.60	5,000	258,000	24,000	Jul 31 04:42 PM
HERMAN JOAN E	Director	Jul 15 '26	Option Exercise	0.00	5,220	0	51,306	Jul 17 05:12 PM
BERTHELSEN SPENCER R	Director	Jul 15 '26	Option Exercise	0.00	5,220	0	161,233	Jul 17 05:12 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Jul 07 '26	Sale	85.46	15,000	1,281,930	0	Jul 09 07:26 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Jul 07 '26	Sale	83.58	5,536	462,693	75,018	Jul 09 07:26 PM
Diaz Allene M.	Director	Jul 07 '26	Option Exercise	47.11	10,111	476,329	13,922	Jul 09 06:07 PM
Diaz Allene M.	Director	Jul 07 '26	Sale	85.42	10,111	863,637	3,811	Jul 09 06:07 PM
Kordasiewicz Holly B.	EVP, Chief Development Officer	Jul 07 '26	Sale	84.30	362	30,517	22,096	Jul 09 06:07 PM
Diaz Allene M.	Director	Jul 07 '26	Proposed Sale	85.42	10,111	863,637		Jul 07 04:33 PM
Kordasiewicz Holly B.	Officer	Jul 07 '26	Proposed Sale	84.30	1,287	108,494		Jul 07 04:30 PM
BENNETT C FRANK	Officer	Jul 07 '26	Proposed Sale	84.95	67,386	5,724,724		Jul 07 04:28 PM
KLEIN JOSEPH III	Director	Jul 01 '26	Option Exercise	39.94	11,518	460,029	22,532	Jul 06 06:49 PM
KLEIN JOSEPH III	Director	Jul 01 '26	Sale	79.04	11,518	910,416	11,014	Jul 06 06:49 PM
KLEIN JOSEPH III	Director	Jul 01 '26	Proposed Sale	79.04	11,518	910,417		Jul 01 05:29 PM
Baroldi Joseph	EVP, Chief Business Officer	Jun 26 '26	Option Exercise	49.19	5,635	277,181	10,304	Jun 30 05:48 PM
Baroldi Joseph	EVP, Chief Business Officer	Jun 26 '26	Sale	80.16	5,635	451,699	4,669	Jun 30 05:48 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Jun 26 '26	Sale	80.00	3,069	245,520	61,470	Jun 30 05:48 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Jun 26 '26	Option Exercise	60.89	26,000	1,583,140	103,114	Jun 30 05:48 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Jun 26 '26	Sale	81.05	26,000	2,107,196	77,114	Jun 30 05:48 PM
Monia Brett P	Chief Executive Officer	Jun 26 '26	Option Exercise	56.78	50,000	2,839,000	295,571	Jun 26 07:09 PM
Monia Brett P	Chief Executive Officer	Jun 25 '26	Option Exercise	32.60	21,072	686,947	266,643	Jun 26 07:09 PM
Monia Brett P	Chief Executive Officer	Jun 24 '26	Option Exercise	32.60	14,565	474,819	260,136	Jun 26 07:09 PM
Monia Brett P	Chief Executive Officer	Jun 26 '26	Sale	80.59	50,000	4,029,500	245,571	Jun 26 07:09 PM
Monia Brett P	Chief Executive Officer	Jun 25 '26	Sale	78.49	21,072	1,653,941	245,571	Jun 26 07:09 PM
Monia Brett P	Chief Executive Officer	Jun 24 '26	Sale	78.41	14,565	1,142,082	245,571	Jun 26 07:09 PM
Swayze Eric	EVP Research	Jun 25 '26	Sale	79.18	10,602	839,492	21,759	Jun 26 07:09 PM
Baroldi Mariana	Member of immediate family of	Jun 26 '26	Proposed Sale	80.16	5,635	451,699		Jun 26 05:48 PM
O'NEIL PATRICK R.	Officer	Jun 26 '26	Proposed Sale	80.00	3,069	245,520		Jun 26 05:47 PM
Schneider Eugene	Officer	Jun 26 '26	Proposed Sale	81.05	47,884	3,880,807		Jun 26 05:43 PM
Swayze Eric	Officer	Jun 25 '26	Proposed Sale	79.16	10,602	839,287		Jun 25 06:53 PM
Kordasiewicz Holly B.	EVP, Chief Development Officer	Jun 12 '26	Option Exercise	53.97	60,846	3,283,664	83,304	Jun 16 05:26 PM
Kordasiewicz Holly B.	EVP, Chief Development Officer	Jun 12 '26	Sale	73.41	60,846	4,466,428	22,458	Jun 16 05:26 PM
BERTHELSEN SPENCER R	Director	Jun 15 '26	Option Exercise	24.42	8,000	195,360	164,013	Jun 16 05:26 PM
BERTHELSEN SPENCER R	Director	Jun 15 '26	Sale	73.49	8,000	587,920	156,013	Jun 16 05:26 PM
BERTHELSEN SPENCER R	Director	Jun 15 '26	Proposed Sale	73.49	8,000	587,920		Jun 15 10:17 AM
Kordasiewicz Holly B.	Officer	Jun 12 '26	Proposed Sale	73.41	60,846	4,466,425		Jun 12 04:29 PM
BERTHELSEN SPENCER R	Director	Jun 01 '26	Option Exercise	24.42	8,000	195,360	164,013	Jun 03 05:34 PM
BERTHELSEN SPENCER R	Director	Jun 01 '26	Sale	75.67	8,000	605,360	156,013	Jun 03 05:34 PM
BERTHELSEN SPENCER R	Director	Jun 01 '26	Proposed Sale	75.67	8,000	605,360		Jun 01 10:47 AM
Monia Brett P	Officer	May 13 '26	Proposed Sale	78.01	100,000	7,801,300		May 13 05:20 PM
LOSCALZO JOSEPH	Director	May 04 '26	Option Exercise	48.74	77,289	3,767,309	113,619	May 06 05:27 PM
LOSCALZO JOSEPH	Director	May 04 '26	Sale	75.06	77,289	5,801,226	36,330	May 06 05:27 PM
KLEIN JOSEPH III	Director	May 01 '26	Option Exercise	47.11	10,111	476,329	21,125	May 05 04:30 PM
KLEIN JOSEPH III	Director	May 01 '26	Sale	73.51	10,111	743,238	11,014	May 05 04:30 PM
LOSCALZO JOSEPH	Director	May 04 '26	Proposed Sale	80.00	54,321	4,345,680		May 04 06:05 PM
Baroldi Joseph	EVP, Chief Business Officer	Apr 28 '26	Sale	71.79	1,626	116,727	44,909	Apr 30 04:21 PM
Baroldi Joseph	Officer	Apr 28 '26	Proposed Sale	71.79	1,626	116,727		Apr 28 04:12 PM
PARSHALL B LYNNE	Director	Apr 15 '26	Sale	76.27	5,000	381,367	51,344	Apr 17 07:19 PM
Jenne Kyle	EVP, Chf GL Pdt Str Ofcr	Apr 15 '26	Option Exercise	0.00	12,226	0	28,615	Apr 17 07:19 PM
Jenne Kyle	EVP, Chf GL Pdt Str Ofcr	Apr 16 '26	Sale	75.17	4,902	368,488	23,713	Apr 17 07:19 PM
Birchler Brian	EVP, Corp and Development Ops	Apr 15 '26	Option Exercise	0.00	1,875	0	68,473	Apr 17 07:19 PM
Birchler Brian	EVP, Corp and Development Ops	Apr 16 '26	Sale	75.04	973	73,016	67,500	Apr 17 07:19 PM
Baroldi Joseph	EVP, Chief Business Officer	Apr 15 '26	Option Exercise	0.00	10,837	0	52,154	Apr 17 07:19 PM
Baroldi Joseph	EVP, Chief Business Officer	Apr 16 '26	Sale	74.56	5,619	418,953	46,535	Apr 17 07:19 PM
Jenne Kyle	Officer	Apr 16 '26	Proposed Sale	75.40	4,902	369,600		Apr 16 06:49 PM
Birchler Brian	Officer	Apr 16 '26	Proposed Sale	75.40	973	73,362		Apr 16 06:47 PM
Baroldi Joseph	Officer	Apr 16 '26	Proposed Sale	75.40	5,619	423,660		Apr 16 06:45 PM
KLEIN JOSEPH III	Director	Apr 01 '26	Option Exercise	39.46	22,321	880,707	33,335	Apr 02 07:43 PM
KLEIN JOSEPH III	Director	Apr 01 '26	Sale	75.55	22,321	1,686,302	11,014	Apr 02 07:43 PM
Devers Shannon L.	EVP, Chief Human Resources Ofc	Apr 02 '26	Sale	74.05	6,193	458,613	16,348	Apr 02 07:43 PM
Diaz Allene M.	Director	Mar 03 '26	Proposed Sale	79.50	68,800	5,469,600		Mar 31 05:28 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Mar 19 '26	Sale	70.97	5,812	412,486	63,890	Mar 23 07:36 PM
Schneider Eugene	Officer	Mar 19 '26	Proposed Sale	70.97	5,812	412,486		Mar 19 04:01 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Mar 16 '26	Option Exercise	51.37	174,999	8,989,092	307,880	Mar 18 05:19 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Mar 16 '26	Sale	72.40	215,048	15,569,014	92,832	Mar 18 05:19 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Mar 17 '26	Sale	73.21	10,172	744,662	82,660	Mar 18 05:19 PM
HOUGEN ELIZABETH L	Officer	Mar 16 '26	Proposed Sale	72.31	225,200	16,284,212		Mar 16 04:32 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Mar 09 '26	Sale	75.25	10,148	763,662	62,211	Mar 11 04:19 PM
Monia Brett P	Chief Executive Officer	Mar 09 '26	Option Exercise	60.89	114,351	6,962,832	369,332	Mar 11 04:19 PM
Monia Brett P	Chief Executive Officer	Mar 10 '26	Option Exercise	60.89	34,103	2,076,532	276,765	Mar 11 04:19 PM
Monia Brett P	Chief Executive Officer	Mar 09 '26	Sale	75.20	126,670	9,525,011	242,662	Mar 11 04:19 PM
Monia Brett P	Chief Executive Officer	Mar 10 '26	Sale	75.92	34,103	2,589,144	242,662	Mar 11 04:19 PM
Jenne Kyle	EVP, Chf GL Pdt Str Ofcr	Mar 10 '26	Option Exercise	44.67	37,277	1,665,128	48,991	Mar 11 04:18 PM
Jenne Kyle	EVP, Chf GL Pdt Str Ofcr	Mar 10 '26	Sale	75.85	37,277	2,827,325	11,714	Mar 11 04:18 PM
Jenne Kyle	Director	Mar 10 '26	Proposed Sale	75.57	58,253	4,402,296		Mar 10 04:00 PM
O'NEIL PATRICK R.	Officer	Mar 09 '26	Proposed Sale	75.25	13,217	994,612		Mar 09 04:16 PM
LOSCALZO JOSEPH	Director	Mar 03 '26	Option Exercise	38.06	832	31,666	37,162	Mar 05 06:14 PM
LOSCALZO JOSEPH	Director	Mar 04 '26	Option Exercise	38.06	200	7,612	36,530	Mar 05 06:14 PM
LOSCALZO JOSEPH	Director	Mar 03 '26	Sale	80.33	832	66,833	36,330	Mar 05 06:14 PM
LOSCALZO JOSEPH	Director	Mar 04 '26	Sale	80.00	200	16,000	36,330	Mar 05 06:14 PM
KLEIN JOSEPH III	Director	Mar 03 '26	Option Exercise	40.76	16,000	652,120	32,346	Mar 05 06:14 PM
KLEIN JOSEPH III	Director	Mar 03 '26	Sale	79.51	21,332	1,696,181	11,014	Mar 05 06:14 PM
Diaz Allene M.	Director	Mar 03 '26	Option Exercise	39.72	40,321	1,601,607	58,689	Mar 05 06:14 PM
Diaz Allene M.	Director	Mar 03 '26	Sale	79.35	54,878	4,354,428	3,811	Mar 05 06:14 PM
Devers Shannon L.	EVP, Chief Human Resources Ofc	Mar 03 '26	Option Exercise	35.97	20,106	723,254	42,647	Mar 05 06:14 PM
Devers Shannon L.	EVP, Chief Human Resources Ofc	Mar 03 '26	Sale	79.40	20,106	1,596,433	22,541	Mar 05 06:14 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Mar 03 '26	Option Exercise	53.73	65,089	3,497,531	165,643	Mar 05 06:13 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Mar 03 '26	Sale	79.23	85,089	6,741,669	80,554	Mar 05 06:13 PM
Baroldi Joseph	EVP, Chief Business Officer	Mar 03 '26	Option Exercise	44.27	1,699	75,215	6,471	Mar 05 06:13 PM
Baroldi Joseph	EVP, Chief Business Officer	Mar 04 '26	Option Exercise	45.71	439	20,066	4,585	Mar 05 06:13 PM
Baroldi Joseph	EVP, Chief Business Officer	Mar 03 '26	Sale	79.36	4,096	325,059	41,317	Mar 05 06:13 PM
Baroldi Joseph	EVP, Chief Business Officer	Mar 03 '26	Sale	80.42	2,124	170,808	4,347	Mar 05 06:13 PM
Baroldi Joseph	EVP, Chief Business Officer	Mar 04 '26	Sale	80.00	439	35,120	4,347	Mar 05 06:13 PM
LOSCALZO JOSEPH	Director	Mar 03 '26	Proposed Sale	80.00	24,000	1,920,000		Mar 03 05:51 PM
Baroldi Mariana	Officer	Mar 03 '26	Proposed Sale	80.00	8,198	655,840		Mar 03 05:43 PM
Baroldi Joseph	Officer	Mar 03 '26	Proposed Sale	79.36	4,096	325,059		Mar 03 05:42 PM
KLEIN JOSEPH III	Director	Mar 03 '26	Proposed Sale	77.07	65,345	5,035,928		Mar 03 05:35 PM
Devers Shannon L.	Officer	Mar 03 '26	Proposed Sale	79.50	39,014	3,101,613		Mar 03 05:34 PM
Swayze Eric	EVP Research	Feb 13 '26	Sale	81.76	15,642	1,278,914	32,105	Feb 13 07:40 PM

ABCL

AbCellera Biologics Inc

IONS

Ionis Pharmaceuticals Inc

Upgrade your Finviz experience